Drug Trial Radar · NCT07004049
Optimising TREATment for Severe Gram-Negative Bacterial Infections
Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Apr 21, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- National University of SingaporeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The University of Queensland; European Clinical Research Alliance for Infectious Diseases (ECRAID)
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria. In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.
Conditions
- Bloodstream Infection
- Ventilator Associated Bacterial Pneumonia
- Hospital Acquired Bacterial Pneumonia
- Carbapenem Resistant Bacterial Infection
- Multidrug Resistance
Interventions
Colistin/Polymyxin B + SulbactamDrug
For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand and Singapore
Colistin/Polymyxin B + Tigecycline/EravacyclineDrug
For carbapenem-resistant Acintobacter, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand and Singapore
Colistin/Polymyxin B + MeropenemDrug
For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia and Singapore
Ceftazidime-avibactam + SulbactamDrug
For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand, Singapore and Australia.
Ceftazidime-avibactam + FosfomycinDrug
For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Malaysia, Thailand and Singapore
Ceftazidime-avibactamDrug
For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
Ceftazidime-avibactam + AztreonamDrug
For carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.
Ceftazidime-avibactam + Colistin/Polymyxin BDrug
For carbapenem-resistant Pseudomonas aeruginosa in China, Malaysia, Thailand, Singapore and Europe.
High-dose meropenemDrug
For carbapenem-resistant Enterobacterales infection in Europe
Meropenem + FosfomycinDrug
For carbapenem-resistant Enterobacterales in Europe
Meropenem-vaborbactamDrug
For carbapenem-resistant Enterobacterales infection in Europe
CefiderocolDrug
For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Europe and Australia.
Ceftolozane-tazobactamDrug
For carbapenem-resistant Pseudomonas aeruginosa in Europe and Australia.
Ceftolozane-tazobactam + MeropenemDrug
For carbapenem-resistant Pseudomonas aeruginosa in Europe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical outcomeTime frame: 28 days post-randomisation
Locations
41 sites in 12 countries. Site status is shown where the registry gives one.
Princess Alexandra Hospital
Brisbane, Australia · Not yet recruiting
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
The Second Affiliated Hospital, Xi'an Jiang Tong University
Xi'an, China · Not yet recruiting
Xuzhou First People's Hospital
Xuzhou, China · Not yet recruiting
American University of Beirut Medical Center
Beirut, Lebanon · Not yet recruiting
Queen Elizabeth I
Kota Kinabalu, Sabah, Malaysia · Not yet recruiting
Queen Elizabeth II
Kota Kinabalu, Sabah, Malaysia · Not yet recruiting
Miri Sarawak Hospital
Miri, Sarawak, Malaysia · Not yet recruiting
Ampang Hospital
Ampang, Selangor, Malaysia · Not yet recruiting
Hospital Sungai Buloh
Sungai Buloh, Selangor, Malaysia · Not yet recruiting
Hamad Medical Corporation
Doha, Qatar · Not yet recruiting
King Saud bin Abdulaziz University for Health Sciences
Riyadh, Saudi Arabia · Not yet recruiting
National University Hospital
Singapore, Singapore, Singapore · Recruiting
Helen Joseph Hospital
Johannesburg, South Africa · Not yet recruiting
Hospital General Universitario Dr. Balmis
Alicante, Spain · Not yet recruiting
Hospital Universitario de Badajoz
Badajoz, Spain · Not yet recruiting
Hospital Universitario de Cruces
Barakaldo, Spain · Not yet recruiting
Hospital del Mar Barcelona
Barcelona, Spain · Not yet recruiting
Hospital Universitario Bellvitge
Barcelona, Spain · Not yet recruiting
Hospital Universitario Reina Sofía Córdoba
Córdoba, Spain · Not yet recruiting
Hospital Universitario San Cecilio
Granada, Spain · Not yet recruiting
Hospital Universitario Virgen de las Nieves
Granada, Spain · Not yet recruiting
Hospital Clínico San Carlos
Madrid, Spain · Not yet recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Spain · Not yet recruiting
Hospital Universitario de La Princesa
Madrid, Spain · Not yet recruiting
Hospital Universitario La Paz
Madrid, Spain · Not yet recruiting
Hospital Regional Universitario de Málaga
Málaga, Spain · Not yet recruiting
Hospital Universitario Virgen de la Victoria
Málaga, Spain · Not yet recruiting
Hospital Álvaro Cunqueiro
Pontevedra, Spain · Not yet recruiting
Hospital Universitario de Donostia
San Sebastián, Spain · Not yet recruiting
Hospital Universitario Marqués de Valdecilla
Santander, Spain · Not yet recruiting
Hospital Universitario Virgen Macarena
Seville, Spain · Not yet recruiting
Hospital Universitario Virgen de Valme
Seville, Spain · Not yet recruiting
Hospital Universitario Virgen del Rocío
Seville, Spain · Not yet recruiting
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Spain · Not yet recruiting
Phramongkutkloa Hospital
Bangkok, Thailand · Not yet recruiting
Rajavithi Hospital
Bangkok, Thailand · Not yet recruiting
Maharaj Nakorn Chiang Mai Hospital, Chiangmai University
Chiang Mai, Thailand · Not yet recruiting
İstanbul Medipol Üniversitesi
Istanbul, Turkey (Türkiye) · Not yet recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.